Anonymous
Guest
Anonymous
Guest
VRX is not really a pharma company, it is more a publicly traded hedge fund that happens to produce pharma products, and as such, the only thing that matters to upper management is reducing ALL costs in making ANY product by whatever means necessary in order for the CEO, the board of directors, and the shareholders to make more money.
Regulatory action would means a few fines, firing a few production ops by laying blame on them, and simply doing the same thing over in the next round. EXACTLY THE SAME WAY AS BEFORE. Again, it is all about money. It is the VRX way.
Once the money lenders realize that VRX has no pipeline plans for future pharma products, and the fact that VRX's debt load will sink the company as it's entire business plan is non sustainable, it will be game over for VRX, but by then, the current CEO, board of directors, and major shareholders will walk away with cash in their pockets, and everyone else in the company will be like Lehman employees
Regulatory action would means a few fines, firing a few production ops by laying blame on them, and simply doing the same thing over in the next round. EXACTLY THE SAME WAY AS BEFORE. Again, it is all about money. It is the VRX way.
Once the money lenders realize that VRX has no pipeline plans for future pharma products, and the fact that VRX's debt load will sink the company as it's entire business plan is non sustainable, it will be game over for VRX, but by then, the current CEO, board of directors, and major shareholders will walk away with cash in their pockets, and everyone else in the company will be like Lehman employees